ArticleBMC infectious diseases2021
Risk factors of recurrent erysipelas in adult Chinese patients: a prospective cohort study.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Association of Cellulitis With Obesity: Systematic Review and Meta-Analysis.JMIR dermatology · 2024Pooled it
- Duration of protective effect after benzathine penicillin G prophylaxis for recurrent cellulitis: a 14-day window of efficacy.Infection · 2026Article
- Recurrent Erysipelas: Clinical Challenges and Strategies for Prevention-A Narrative Literature Review.Biomedicines · 2025Review
- Temporal association and risk factors for periprosthetic joint infection following erysipelas in total hip and knee arthroplasty.Archives of orthopaedic and trauma surgery · 2025Article
- Primary and Recurrent Erysipelas-Epidemiological Patterns in a Single-Centre Retrospective Analysis.Journal of clinical medicine · 2025Article
- The intricate pathogenicity of Group AVirulence · 2024Review
- Development and validation of the Baseline Recurrence Risk in Cellulitis (BRRISC) score.The Journal of infection · 2024Article
- Recurrent Cellulitis: Who is at Risk and How Effective is Antibiotic Prophylaxis?International journal of general medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErysipelas is a common skin infection that is prone to recur. Recurrent erysipelas has a severe effect on the quality of life of patients. The present study aimed to investigate the risk factors of recurrent erysipelas in adult Chinese patients.
methodsA total of 428 Chinese patients with erysipelas who met the inclusion criteria were studied. The patients were divided into the nonrecurrent erysipelas group and the recurrent erysipelas group. Clinical data were collected on the first episode and relapse of erysipelas. The patients were followed up every 3 months. Statistical analysis was performed to analyze and determine the risk factors of erysipelas relapse.
resultsUnivariate analysis was performed to analyze the data, including surgery, types of antibiotics administered in the first episode, obesity, diabetes mellitus, venous insufficiency, lymphedema, and malignancy. The differences between the groups were statistically significant (p < 0.05). The Cox proportional hazards regression model analysis showed that the final risk factors included surgery, obesity, diabetes mellitus, venous insufficiency, and lymphedema.
conclusionsSurgery, obesity, diabetes mellitus, venous insufficiency, and lymphedema are considered as risk factors for recurrent erysipelas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.